Britain’s national healthcare provider, NHS England, says the UK is on track to eliminate hepatitis C by 2025, following a “concerted effort to find people at risk.”
Eliminating the virus in that timeframe would represent a five-year improvement on the global target set by the World Health Organization to achieve the milestone.
People with hepatitis C have benefitted from a dramatic improvement in treatment outcomes in recent years, thanks to the development of a curative antiviral by Gilead Sciences (Nasdaq: GILD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze